Water and energy-based optimisation of a “MiniCity”: A system dynamics approach

Urban sprawls in Australia and several countries around the world have introduced a number of social, economic, and environmental issues for residents and urban planners, highlighting the need for new urban development concepts. In recent years, the concept of a vertical sprawl called "MiniCity" has been presented. The objective of a successful "MiniCity", compared to traditional high-rises, is to be as self-sufficient and self-contained as possible; whilst also minimising issues such as car dependency, loss of agricultural land and natural habitats, water and air pollution, and poorer health and wellbeing, which are common for residents in low-density, low-rise areas and developments. To date however, the viability of a MiniCity has yet to be properly addressed. Arguably, the predominant needs for a community are water, energy and food. In this research study, a System Dynamics model was developed to simulate supply and demand of the water and energy systems, as well as their interaction, for a hypothetical MiniCity located in South-East Queensland, Australia. The models were conceptualised based on expert knowledge, with data and equations collected from local Gold Coast sources and from the literature. Preliminary results show the complex, but expected, dynamics and interactions between the two systems, and their dependence to critical input parameters, such as climate data, roof area, number of floors, to name a few. Future work will focus on adding other critical modelling components such as food production and thus analyse the water-energy-food nexus. The final, validated model will allow the optimisation of critical MiniCity parameters and the identification of suitable locations that can maximise the socio-economic and environmental viability of the MiniCity.Full Tex

Doppler images of II Pegasi for 2004-2010

Aims. We study the spot activity of II Peg during the years 2004-2010 to determine long- and short-term changes in the magnetic activity. In a previous study, we detected a persistent active longitude, as well as major changes in the spot configuration occurring on a timescale of shorter than a year. The main objective of this study is to determine whether the same phenomena persist in the star during these six years of spectroscopic monitoring. Methods. The observations were collected with the high-resolution SOFIN spectrograph at the Nordic Optical Telescope. The temperature maps were calculated using a Doppler imaging code based on Tikhonov regularization. Results. We present 12 new temperature maps that show spots distributed mainly over high and intermediate latitudes. In each image, 1-3 main active regions can be identified. The activity level of the star is clearly lower than during our previous study for the years 1994-2002. In contrast to the previous observations, we detect no clear drift of the active regions with respect to the rotation of the star. Conclusions. Having shown a systematic longitudinal drift of the spot-generating mechanism during 1994-2002, the star has clearly switched to a low-activity state for 2004-2010, during which the spot locations appear more random over phase space. It could be that the star is near to a minimum of its activity cycle.Comment: Accepted for publication in Astron. and Astrophys., 8 pages, 5 figure

The impact of COVID-19 on cancer care and oncology clinical research: an experts' perspective

The coronavirus disease-19 (COVID-19) pandemic promises to have lasting impacts on cancer clinical trials that could lead to faster patient access to new treatments. In this article, an international panel of oncology experts discusses the lasting impacts of the pandemic on oncology clinical trials and proposes solutions for clinical trial stakeholders, with the support of recent data on worldwide clinical trials collected by IQVIA. These lasting impacts and proposed solutions encompass three topic areas. Firstly, acceleration and implementation of new operational approaches to oncology trials with patient-centric, fully decentralized virtual approaches that include remote assessments via telemedicine and remote devices. Geographical differences in the uptake of remote technology, including telemedicine, are discussed in the article, focusing on the impact of the local adoption of new operational approaches. Secondly, innovative clinical trials. The pandemic has highlighted the need for new trial designs that accelerate research and limit risks and burden for patients while driving optimization of clinical trial objectives and endpoints, while testing is being minimized. Areas of considerations for clinical trial stakeholders are discussed in detail. In addition, the COVID-19 pandemic has exposed the underrepresentation of minority groups in clinical trials; the approach for oncology clinical trials to improve generalizability of efficacy and outcomes data is discussed. Thirdly, a new problem-focused collaborative framework between oncology trial stakeholders, including decision makers, to leverage and further accelerate the innovative approaches in clinical research developed during the COVID-19 pandemic. This could shorten timelines for patient access to new treatments by addressing the cultural and technological barriers to adopting new operational approaches and innovative clinical trials. The role of the different stakeholders is described, with the aim of making COVID-19 a catalyst for positive change in oncology clinical research and eventually in cancer care

On the Contribution of Unresolved Galactic Stars to the Diffuse Soft X-ray Background

Using stellar luminosity functions derived from ROSAT data, the contributions of Galactic stars to the diffuse X-ray background are calculated for ROSAT PSPC energy bands. The model follows that of Guillout et al. (1996), but uses ROSAT rather than {\it Einstein} data to determine the intrinsic luminosity distributions. The model adequately predicts the numbers of stellar sources observed in deep ROSAT surveys. The contribution of unresolved stellar sources to the ROSAT All-Sky Survey at the Galactic poles is 6.85, 4.76, and 4.91 $\times$ counts s$^{-1}$ arcmin$^{-2}$ in bands R12 (1/4 keV), R45(3/4 keV), and R67(1.5 keV), respectively, which is equivalent to 4.66, 31.3 and 26.9 $\times10^{-14}$ ergs cm$^{-2}$ s$^{-1}$ deg$^{-2}$.Comment: 14 pages, 8 figures, accepted by Ap

The occurrence and management of fluid retention associated with TKI therapy in CML, with a focus on dasatinib

Tyrosine kinase inhibitors (TKIs) like dasatinib and nilotinib are indicated as second-line treatment for chronic myeloid leukemia resistant or intolerant to the current first-line TKI imatinib. These are agents are well tolerated, but potent and as such should be monitored for potentially serious side-effects like fluid retention and pleural effusions. Here we present key clinical trial data and safety considerations for all FDA approved TKIs in context for effective management of fluid retention and pleural effusions. Altering the dasatinib regimen from 70 mg twice daily to 100 mg daily reduces the risk of pleural effusion for patients taking dasatinib. Should pleural effusion develop, dasatinib should be interrupted until the condition resolves. Patients with a history of pleural effusion risk factors should be monitored closely while taking dasatinib. Patients receiving imatinib and nilotinib are not without risk of fluid retention. All patients should also be educated to recognize and report key symptoms of fluid retention or pleural effusion. Pleural effusions are generally managed by dose interruption/reduction and other supportive measures in patients with chronic myeloid leukemia receiving dasatinib therapy

Blinatumomab compared with standard of care for the treatment of adult patients with relapsed/refractory Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia

Background A single‐arm, phase 2 trial demonstrated the efficacy and safety of blinatumomab, a bispecific T‐cell–engaging antibody construct, in patients with relapsed/refractory (r/r) Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia (ALL), a rare hematologic malignancy with limited treatment options. This study compared outcomes with blinatumomab with those of a historical control treated with the standard of care (SOC). Methods The blinatumomab trial enrolled adult patients with Ph+ ALL who were r/r to at least 1 second‐generation tyrosine kinase inhibitor (n = 45). Propensity score analysis (PSA) was used to compare outcomes with blinatumomab with those of an external cohort of similar patients receiving SOC chemotherapy (n = 55). The PSA mitigated confounding variables between studies by adjusting for imbalances in the age at diagnosis and start of treatment, sex, duration from diagnosis to most recent treatment, prior allogeneic hematopoietic stem cell transplantation, prior salvage therapy, and number of salvage therapies. Bayesian data augmentation was applied to improve power to 80% with data from a phase 3 blinatumomab study in r/r Philadelphia chromosome–negative ALL. Results In the PSA, the rate of complete remission or complete remission with partial hematologic recovery was 36% for blinatumomab and 25% for SOC, and this resulted in an odds ratio of 1.54 (95% confidence interval [CI], 0.61‐3.89) or 1.70 (95% credible interval [CrI], 0.94‐2.94) with Bayesian data augmentation. Overall survival favored blinatumomab over SOC, with a hazard ratio of 0.81 (95% CI, 0.57‐1.14) or 0.77 (95% CrI, 0.61‐0.96) with Bayesian data augmentation. Conclusions These results further support blinatumomab as a treatment option for patients with r/r Ph+ ALL